Company Analysis

Kura Oncology, Inc. (KURA)

Nasdaq: KURA · Pharmaceutical Preparations · San Diego, CA · filing with the SEC since 2008
Grade5.9
◀ Past 7.3● Present 4.7▶ Future 6.2
2 est.

Who runs Kura Oncology, Inc.

Officers and directors as they report to the SEC on Forms 3, 4 and 5, named as filed
Chief executive, as filed
Wilson Troy Edward
President and CEO. First filing Mar 2015, latest Aug 24, 2026, 11 filings in all.
Officers reporting now
8
of 15 people with a filing in the last fifteen months
Directors reporting now
7
28 people on the record since 2015
Officerssales are open-market, Sep 30, 2025 to Sep 30, 2026
NameTitle as filedFirst filingLatest filingSales, 12 months
Ford KathleenChief Operating OfficerAug 2019Sep 29, 20265 · $200,000
Bair Teresa BrophyChief Legal OfficerOct 2021Sep 29, 20267 · $700,000
Leoni MollieChief Medical OfficerJan 2025Sep 29, 20268 · $1.5M
Powl Brian T.Chief Commercial OfficerAug 2023Sep 29, 20269 · $700,000
Doyle Thomas JamesSVP, Finance & AccountingFeb 2022Sep 29, 20267 · $200,000
Burrows FrancisChief Scientific OfficerJan 2025Sep 25, 20263 · $500,000
Fulk JenniferChief Financial OfficerSep 2026Sep 10, 2026none
Wilson Troy EdwardPresident and CEOMar 2015Aug 24, 2026none
Directorssales are open-market, Sep 30, 2025 to Sep 30, 2026
NameRoleFirst filingLatest filingSales, 12 months
Collins Helen LouisedirectorJul 2021Jun 4, 2026none
Hasnain FaheemdirectorApr 2015Jun 4, 20261 · $100,000
Malley ThomasdirectorOct 2015Jun 4, 2026none
Parks Diane L.directorOct 2019Jun 4, 2026none
Schafer CaroldirectorJun 2021Jun 4, 2026none
Szela Mary TdirectorNov 2018Jun 4, 2026none
Vasconcelles MichaeldirectorSep 2024Jun 4, 2026none
Earlier names on the record14, newest filing first

A person is listed as reporting now after a filing in the last fifteen months. The record shows when someone last filed; it does not say why they stopped. Each name links to the filings on sec.gov.

SI Assistanton KURA · research, not advice